PURPOSE: REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indicate potential for synergy between reovirus and chemotherapeutic agents. A multicenter, phase I dose escalation study was designed to assess the safety of combining reovirus with docetaxel chemotherapy in patients with advanced cancer. EXPERIMENTAL DESIGN: Patients received 75 mg/m(2) docetaxel (day 1) and escalating doses of reovirus up to 3 × 10(10) TCID(50) (days 1-5) every 3 weeks. RESULTS: Twenty-five patients were enrolled, and 24 patients were exposed to treatment, with 23 completing at least one cycle and 16 suitable for response assessment. Dose-limiting toxicity of grade 4 neutropenia was seen in one patient, but the maximum tolerated dose was not reached. Antitumor activity was seen with one complete response and three partial responses. A disease control rate (combined complete response, partial response, and stable disease) of 88% was observed. Immunohistochemical analysis of reovirus protein expression was observed in posttreatment tumor biopsies from three patients. CONCLUSION: The combination of reovirus and docetaxel is safe, with evidence of objective disease response, and warrants further evaluation in a phase II study at a recommended schedule of docetaxel (75 mg/m(2), three times weekly) and reovirus (3 × 10(10) TCID(50), days 1-5, every 3 weeks).
PURPOSE: REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indicate potential for synergy between reovirus and chemotherapeutic agents. A multicenter, phase I dose escalation study was designed to assess the safety of combining reovirus with docetaxel chemotherapy in patients with advanced cancer. EXPERIMENTAL DESIGN:Patients received 75 mg/m(2) docetaxel (day 1) and escalating doses of reovirus up to 3 × 10(10) TCID(50) (days 1-5) every 3 weeks. RESULTS: Twenty-five patients were enrolled, and 24 patients were exposed to treatment, with 23 completing at least one cycle and 16 suitable for response assessment. Dose-limiting toxicity of grade 4 neutropenia was seen in one patient, but the maximum tolerated dose was not reached. Antitumor activity was seen with one complete response and three partial responses. A disease control rate (combined complete response, partial response, and stable disease) of 88% was observed. Immunohistochemical analysis of reovirus protein expression was observed in posttreatment tumor biopsies from three patients. CONCLUSION: The combination of reovirus and docetaxel is safe, with evidence of objective disease response, and warrants further evaluation in a phase II study at a recommended schedule of docetaxel (75 mg/m(2), three times weekly) and reovirus (3 × 10(10) TCID(50), days 1-5, every 3 weeks).
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: H Petrowsky; G D Roberts; D A Kooby; B M Burt; J J Bennett; K A Delman; S F Stanziale; T M Delohery; W P Tong; H J Federoff; Y Fong Journal: J Virol Date: 2001-08 Impact factor: 5.103
Authors: Timothy M Pawlik; Hideo Nakamura; John T Mullen; Hideki Kasuya; Sam S Yoon; Soundararajalu Chandrasekhar; E Antonio Chiocca; Kenneth K Tanabe Journal: Cancer Date: 2002-09-01 Impact factor: 6.860
Authors: Radharani Gollamudi; Mohammad H Ghalib; Kavita K Desai; Imran Chaudhary; Benny Wong; Mark Einstein; Matthew Coffey; George M Gill; Karl Mettinger; John M Mariadason; Sridhar Mani; Sanjay Goel Journal: Invest New Drugs Date: 2009-07-02 Impact factor: 3.850
Authors: Karishma Rajani; Christopher Parrish; Timothy Kottke; Jill Thompson; Shane Zaidi; Liz Ilett; Kevin G Shim; Rosa-Maria Diaz; Hardev Pandha; Kevin Harrington; Matt Coffey; Alan Melcher; Richard Vile Journal: Mol Ther Date: 2015-08-27 Impact factor: 11.454
Authors: E Anders Kolb; Valerie Sampson; Deborah Stabley; Alexa Walter; Katia Sol-Church; Timothy Cripe; Pooja Hingorani; Charlotte Hsieh Ahern; Brenda J Weigel; James Zwiebel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2015-02-27 Impact factor: 3.167
Authors: Eleni M Karapanagiotou; Victoria Roulstone; Katie Twigger; Mercel Ball; Maryanne Tanay; Chris Nutting; Kate Newbold; Martin E Gore; James Larkin; Konstantinos N Syrigos; Matt Coffey; Brad Thompson; Karl Mettinger; Richard G Vile; Hardev S Pandha; Geoff D Hall; Alan A Melcher; John Chester; Kevin J Harrington Journal: Clin Cancer Res Date: 2012-02-07 Impact factor: 12.531
Authors: Victoria Roulstone; Malin Pedersen; Joan Kyula; David Mansfield; Aadil A Khan; Grainne McEntee; Michelle Wilkinson; Eleni Karapanagiotou; Matt Coffey; Richard Marais; Adel Jebar; Fiona Errington-Mais; Alan Melcher; Richard Vile; Hardev Pandha; Martin McLaughlin; Kevin J Harrington Journal: Mol Ther Date: 2015-01-26 Impact factor: 11.454
Authors: Jason P Fernandes; Francisca Cristi; Heather E Eaton; Patricia Chen; Sarah Haeflinger; Isabelle Bernard; Mary M Hitt; Maya Shmulevitz Journal: J Virol Date: 2019-10-29 Impact factor: 5.103
Authors: David E Cohn; Michael W Sill; Joan L Walker; David O'Malley; Christa I Nagel; Teresa L Rutledge; William Bradley; Debra L Richardson; Katherine M Moxley; Carol Aghajanian Journal: Gynecol Oncol Date: 2017-07-27 Impact factor: 5.482
Authors: Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester Journal: Clin Cancer Res Date: 2011-05-16 Impact factor: 12.531
Authors: Don G Morris; Xiaolan Feng; Lisa M DiFrancesco; Kevin Fonseca; Peter A Forsyth; Alexander H Paterson; Matt C Coffey; Brad Thompson Journal: Invest New Drugs Date: 2012-08-12 Impact factor: 3.850